MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis

PURPOSE: Lenvatinib is a long-awaited alternative to Sorafenib for first-line targeted therapy of patients with advanced hepatocellular carcinoma (HCC). However, resistance to Lenvatinib results in tumor progression and has become a major obstacle to improving the prognosis of HCC patients. Explorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ting, Yu, Jiajian, Lu, Lu, Zhang, Yize, Zhou, Yadong, Zhou, Yong, Huang, Fengling, Sun, Lu, Guo, Zhixian, Hou, Guojun, Dong, Zihui, Wang, Bibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338827/
https://www.ncbi.nlm.nih.gov/pubmed/33974236
http://dx.doi.org/10.1007/s13402-021-00605-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338827/
https://www.ncbi.nlm.nih.gov/pubmed/33974236
http://dx.doi.org/10.1007/s13402-021-00605-0

Ejemplares similares